ABL DiagnosticsXPAR:ABLD +0.76%51 ROA % is 11.61% as of Dec. 2025, which is 829% above its 10-year median of 1.25. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 81.2% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ABL Diagnostics's annualizedNet Income for the quarter that ended in Dec. 2025 was €1.40 Mil.
ABL Diagnostics's average Total Assets over the quarter that ended in Dec. 2025 was €12.03 Mil. Therefore, ABL Diagnostics's annualized ROA % for the quarter that ended in Dec. 2025 was 11.61%.
The historical rank and industry rank for ABL Diagnostics's ROA % or its related term are showing as below:
XPAR:ABLD'
s ROA % Range Over the Past 10 Years
Min: -6.96 Med: 1.25 Max: 21.27
Current: 8.26
During the past 13 years, ABL Diagnostics's highest ROA % was 21.27%. The lowest was -6.96%. And the median was 1.25%.
XPAR:ABLD's ROA % is ranked better than 81.2% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.79
vs XPAR:ABLD: 8.26
ABL Diagnostics (XPAR:ABLD) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
ABL Diagnostics ROA % Related Terms
ABL Diagnostics ROA % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, ABL Diagnostics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's ROA % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
ABL Diagnostics (XPAR:ABLD) has a ROA % of 11.61% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ABL Diagnostics and its competitors. This is 829% above median its historical median of 1.25. According to the industry distribution chart, ABL Diagnostics ranks #128 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 18.8%.
Is ABL Diagnostics' ROA % too high?
ABL Diagnostics' current ROA % of 11.61% is 829% above median its 10-year median of 1.25. The Healthcare Providers & Services industry median ROA % is 1.79. ABL Diagnostics' value of 11.61% is 548.6% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #128 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #128 out of 681 companies for ROA %. This places ABL Diagnostics in the top 19% of its industry — outperforming the majority of peers. The industry median ROA % is 1.79. ABL Diagnostics' value of 11.61% is 548.6% above this benchmark. While the company's 10-year median is 1.25 vs. the industry median of 1.79, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.79, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current ROA % of 11.61% is 548.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current ROA % is 11.61%, which is 829% above median its own 10-year median of 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current ROA % is 11.61%, which is 829% above median its 10-year median of 1.25 and 548.6% above the Healthcare Providers & Services industry median of 1.79. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current ROA % is 11.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
ROA %: 11.61% (829% above median its 10-year median of 1.25)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 548.6% above the Healthcare Providers & Services median (#128 of 681)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
